Account Options>

  1. Sign in
Falconi Line
 Share
The version of the browser you are using is no longer supported. Please upgrade to a supported browser.Dismiss

 
$
%
123
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
|
 
Still loading...
ABCDEFGHIJKL
1
Falconi Line  2429/10/2018
2
DateShort PositionSP Increase DecreasePPS close at DatePPS Average Close in periodPPS High in periodPPS Low in periodAverage Daily Volume In Period PPS Average Change in period PPS AV Increase Decrease Since ApprovalNotesLinks
3
10/29/201012879047 2.42 1.31 19,700,100Short Position Prior to Approval Suspected covered ?
4
5
11/15/201014,838,65814,838,658 4.76 4.74 5.80 4.21 11,036,100 First NASDAQ Data Following Approval of Nuedexta. Ist November high volume 55,467,900 By the 11/15/10 14,838,658 shares are short ? is it a new short position.
6
11/30/201012,377,768-2,460,890 4.25 4.36 4.74 4.20 3,533,340 -0.38 -0.38 lowest short position since approval. AVNR Prospectus Jefferies Sole Manager. Link to full prospectus https://docs.google.com/file/d/0BynSySvZi_MFZGNFZXhNTDJZM0k/edit
7
12/15/201013,423,3431,045,575 3.74 3.91 4.32 3.70 3,626,763 -0.45 -0.83 http://www.jefferies.com/cositemgr.pl/html/ProductsServices/index.shtml
8
12/31/201015,226,0021,802,659 4.08 4.11 4.34 3.70 2,712,636 0.20 -0.63 USA & EU Health Care Comparison Chart USA 100% EU 75%https://docs.google.com/spreadsheet/ccc?key=0AinSySvZi_MFdExnNkRNVE1aQUVveVcyZmlDU2JXOFE#gid=0
9
1/14/201116,729,4931,503,491 4.45 4.30 4.53 4.02 2,033,040 0.19 -0.44 Avanir announce proposed public offering Nov 16thhttp://messages.finance.yahoo.com/Business_%26_Finance/Investments/Stocks_%28A_to_Z%29/Stocks_A/threadview?bn=27718&tid=169995&mid=170085
10
1/31/201118,157,9511,428,458 4.05 4.20 4.50 3.96 2,229,970 -0.10 -0.54 Jan. 31, 2011 Avanir Announce Nuedexta Launchhttp://messages.finance.yahoo.com/Stocks_%28A_to_Z%29/Stocks_A/threadview?m=ts&bn=27718&tid=170809&mid=170809&tof=-1&rt=1&frt=2&off=1
11
2/15/201120,968,0942,810,143 4.124.024.223.753,361,218 -0.18-0.72
12
2/28/201125,279,6064,311,512 3.773.753.953.464,420,637 -0.27-0.99 EMA Conditional marketing authorisation details Linkhttps://docs.google.com/file/d/0BynSySvZi_MFdjB2QlJpRy1nZUE/edit
13
3/15/201129,286,1444,006,538 3.913.754.133.354,068,454 0-0.99
14
3/31/201130,028,579742,435 4.083.824.183.673,584,833 0.07-0.92 Canaccord Genuity Reiterates a 'Buy' 3/16/2011 Price Target  $10  http://www.streetinsider.com/Analyst+Comments/Canaccord+Genuity+Reiterates+a+Buy+on+Avanir+Pharmaceuticals+%28AVNR%29%3B+Nuedexta+Launch%3A+First+Six+Weeks+Modest%2C+But+Very+Preliminary/6371104.html
15
4/15/201132,797,7042,769,125 3.863.924.133.714,960,363 0.1-0.82 Doctor Richard Smith Explainshttp://newmedia.ufm.edu/gsm/index.php?title=Rsmithdegenerative
16
4/29/201133,037,971240,267 4.374.084.63.727,455,840 0.16-0.66 Beyond the Dopamine Hypothesis to the NMDA Glutamate Receptor Hypofunction Hypothesis of Schizophreniahttp://www.cnsspectrums.com/aspx/articledetail.aspx?articleid=1037
17
5/13/201132,890,324-147,647 3.864.024.63.677,871,380 -0.06-0.72Fails to Deliver link provided by Upton Teahttp://failstodeliver.com/default.aspx
18
5/31/201130,890,181-2,000,143 4.514.364.83.7811,972,125 0.34-0.38 PPS Rising. Short position decreases. Senate Letter regarding Drug Price. http://www.thestreet.com/story/11132797/1/avanir-congress-gripes-about-high-drug-price.html
19
6/15/201130,904,43914,258 3.663.954.663.5810,371,936 -0.41-0.79 06/03/11 Highest 1 day Volume since approval 22,632,800
20
6/30/201131,315,711411,272 3.363.483.7434,662,218 -0.47-1.26 ,
21
7/15/201133,045,4971,729,786 3.393.433.583.231,231,233 -0.05-1.31 NMDA Receptor Ketamine for Depression, Dex = NMDA receptorhttp://ketaminedepression.org/category/ketamine/
22
7/29/201135,392,9142,347,417 3.753.724.053.362,326,160 0.29-1.02 Peak Short Position
23
8/15/201134,677,841-715,073 2.993.213.932.643,093,018-0.51-1.53 NMDA Antagonists for CFS/ME and Fibromyalgiahttp://suite101.com/article/nmda-antagonists-cfsme-and-fm-a62033
24
8/31/201134,168,643-509,198 2.842.773.022.462,093,475-0.44-1.97 EU Zone problems continue
25
9/15/201133,866,728-301,915 2.892.812.992.552,421,3700.04-1.93 Average pps increase .04 Start of Trend ? I Yr Target = 7.9
26
9/30/201132,784,568-1,082,160 2.862.913.092.71,564,3730.10-1.83 Average pps increase .10 Slight upward trend continues
27
10/14/201132,309,332-475,236 3.223.023.252.462,022,4400.11-1.72 Average pps increase .11 Slight upward trend continues.
28
10/31/201131,333,059-976,273 2.992.903.182.73811,255-0.12-1.84Multi indication threadhttp://messages.finance.yahoo.com/Stocks_%28A_to_Z%29/Stocks_A/threadview?m=tm&bn=27718&tid=291541&mid=291541&tof=-1&rt=2&frt=2&off=1
29
11/15/201130,832,083-500,976 2.672.742.972.58717,881-0.16-2.00Lowest Av Volume Downward trend continued. I Yr Target 6.30 http://money.cnn.com/2011/11/03/markets/jefferies_hedgefunds/index.htm
30
11/30/201129,931,324-900,759 2.462.362.821.981,868,090-0.38-2.38Nov. 17,  AVNR) announced today that the (EMA) has accepted the filing of the  (MAA) for NUEDEXTAhttp://www.reuters.com/article/2011/11/17/idUS138374+17-Nov-2011+PRN20111117
31
12/15/201127,708,954-2,222,370 1.852.282.641.812,652,672-0.08-2.46Annual Report 12/12/11 JEF lowers to 3 from 3.5 12/13/11
32
12/30/201126,343,219-1,365,735 2.051.92.071.772,132,940-0.38-2.84New Low 12/16/11 = 1.77 Yahoo 1 Yr Target 6.40 Raised to 8Round 3 ? Commenced July 12 
33
1/13/201226,249,597-93,622 2.762.362.8221,722,9560.46-2.38Positive Slide Presentation at J P Morgan . High on 01/12/12
34
1/31/201226,325,47275,875 2.942.862.952.71,183,9090.50-1.88MLV & Co Initiated 1Yr Target Revised down to 6.33
35
2/15/201225,928,909-396,563 2.973.073.382.82,108,6640.21-1.67High of 3.38 0n the 03/02/12 ........... Link to 2012 10K >http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9MTI0MzQyfENoaWxkSUQ9LTF8VHlwZT0z&t=1
36
2/29/201225,343,278-585,631 2.762.873.042.76874,633-0.20-1.87Concert License Agreement 02/29/12 http://finance.yahoo.com/news/avanir-pharmaceuticals-concert-pharmaceuticals-announce-130000703.html
37
3/15/201225,129,085-214,193 3.122.933.202.481,507,3550.06-1.81PPS Low on the 03/06/12 v= 2.36M 2nd Highest in period
38
3/30/201224,017,543-1,111,542 3.423.43.563.11,607,3540.47-1.34AVNR appoint Rohan Palekar to the position of senior vice president and chief commercial officer. http://finance.yahoo.com/news/avanir-pharmaceuticals-announces-appointment-rohan-123000783.html
39
4/13/201224,211,698194,155 2.93.183.562.91,109,311-0.22-1.56Avanir to Present at BioCentury 04/20/12 Slide Presentationhttps://docs.google.com/file/d/0BynSySvZi_MFeTRNdjRVRm43Zkk/edit
40
4/30/201224,153,824-57,874 3.052.973.092.85766,273-0.21-1.77Script growth continues as indicated on Onlyfacts graphhttp://i1134.photobucket.com/albums/m605/ofppublic/Image1-15.jpg
41
5/15/201223,887,563-266,261 2.892.923.082.651,232,064-0.05-1.82Q2 Earnings Call transcript incorporating loan agreement note.http://seekingalpha.com/article/570541-avanir-pharmaceuticals-ceo-discusses-f2q2012-results-earnings-call-transcript?source=yahoo
42
5/31/201223,752,272-135,291 2.972.8732.71,000,427-0.05-1.875/29/2012 AVNR Present at Jefferies 2012 Global Healthcare Conference Link for 30 days onlyhttp://wsw.com/webcast/jeff68/avnr/
43
6/15/201223,008,015-744,257 3.052.883.062.75928,7550.01-1.86Avanir Pharmaceuticals Announces FDA Acceptance Of IND For AVP-923 For The Treatment Of Agitation In Patients With Alzheimer's Diseasehttp://finance.yahoo.com/news/avanir-pharmaceuticals-announces-fda-acceptance-123000563.html
44
6/29/201221,940,019-1,067,996 3.923.564.053.021,994,9000.68-1.18Observation pps not above 4.05 since peak short position. Avanir Corporate presentation slides June 2012 link.https://docs.google.com/file/d/0BynSySvZi_MFaFMtTjM0czAzM00/edit
45
7/13/201220,621,450-1,318,569 3.33.714.053.291,848,8220.15-1.03Avanir Pharmaceuticals Announces Notice Of Allowance Of U.S. Patent Application Covering NUEDEXTAhttp://www.redorbit.com/news/health/1112649160/avanir_pharmaceuticals_announces_notice_of_allowance_of_us_patent_application/
46
7/31/201220,097,427-524,023 2.863.033.372.781,048,833-0.68-1.71http://www.fool.com/investing/general/2012/08/01/what-to-expect-from-avanir-pharmaceuticals.aspx
47
8/15/201220,246,146148,719 32.93.032.76813,100-0.13-1.84Avanir Pharmaceuticals' CEO Presents at Canaccord Genuity 32nd Annual Growth Conference (Transcript)  http://seekingalpha.com/article/806341-avanir-pharmaceuticals-ceo-presents-at-canaccord-genuity-32nd-annual-growth-conference-transcript?source=yahoo
48
8/31/201220,292,39246,246 3.323.043.52.78912,3670.14-1.70Avanir Corporate Presentation Slides August 2012https://docs.google.com/file/d/0BynSySvZi_MFVW9kUmZtdzd2am8/edit
49
9/14/201220,366,06673,674 3.463.373.533.13997,5000.33-1.37Avanir Pharmaceuticals Announces Enrollment Of First Patient In Study Of AVP-923 For The Treatment Of Agitation In Patients With Alzheimer's Disease. Form S3 Link Cowen Share Dealinghttp://secfilings.nasdaq.com/filingFrameset.asp?FileName=0001193125%2D12%2D344032%2Etxt&FilePath=%5C2012%5C08%5C08%5C&CoName=AVANIR+PHARMACEUTICALS%2C+INC%2E&FormType=S%2D3&RcvdDate=8%2F8%2F2012&pdf=
50
9/28/201219,833,935-532,131 3.23.463.943.21,583,1000.09-1.28Record prescriptions of 2,552 September 7.AVNR expects an opinion from CHMP  by the first calendar quarter of 2013. Link UBS Global Life Sciences Conference (Transcript)http://seekingalpha.com/article/879021-avanir-pharmaceuticals-management-presents-at-ubs-global-life-sciences-conference-transcript?source=yahoo
51
10/15/201220,316,806482,871 3.023.23.572.94931,827-0.26-1.54Hypotheses regarding rapid-acting, treatment-refractory,and conventional antidepressant activity of dextromethorphan and dextrorphan ;-) Cowen Initiated with Outperform $6https://docs.google.com/file/d/0BynSySvZi_MFekVHeWZEeFhYYjQ/edit
52
10/31/201220,189,512-127,294 2.863.113.262.82796,570-0.09-1.63The Michael J. Fox Foundation Awards Grant To Support Avanir Pharmaceuticals' Clinical Study Of AVP-923 For Levodopa Induced Dyskinesia In Parkinson's Disease 10/23/2012http://finance.yahoo.com/news/michael-j-fox-foundation-awards-123000938.html
53
11/15/201221,327,2171,137,705 2.162.592.922.071,290,981-0.52-2.15Avanir Pharmaceuticals To Present At 24th Annual Piper Jaffray Healthcare Conference Temporary Entry ANY News to be postedhttp://finance.yahoo.com/news/avanir-pharmaceuticals-present-24th-annual-133000771.html
54
11/30/201222,215,573888,356 2.642.62.922.271,590,2000.01-2.14AVNR Pre-Announces Preliminary Fiscal 2012 Fourth Quarter Results And Provides Clinical Study Update D/DM AVP 786http://phoenix.corporate-ir.net/phoenix.zhtml?c=61699&p=irol-newsArticle&ID=1761998&highlight=
55
12/14/201222,636,244420,671 2.42.582.742.341,006,780-0.02-2.16Avanir CC Call transcript added to work book read on next tab  AVNR Transcript 12 12 2012. 1OK Year End Sept 2012 Linkhttp://secfilings.nasdaq.com/filingFrameset.asp?FileName=0001193125%2D12%2D501967%2Etxt&FilePath=%5C2012%5C12%5C13%5C&CoName=AVANIR+PHARMACEUTICALS%2C+INC%2E&FormType=10%2DK&RcvdDate=12%2F13%2F2012&pdf=
56
12/31/201222,094,167-542,077 2.622.642.712.49951,2360.06-2.10Avanir Year End Interactive report covering, letter to shareholders, pipeline, and financials- Linkhttps://www.avanir.com/ar2012/
57
1/15/201322,140,52046,353 3.163.033.32.681,189,6700.39-1.71Avanir Corporate Deck Presentation Slides Jan 2013https://docs.google.com/file/d/0BynSySvZi_MFX21Kb0VnQUVLWEU/edit
58
1/31/201321,608,075-532,445 2.923.023.152.91,208,954-0.01-1.72 Weekly prescriptions grew more than 28% To a record high of 3523 Turns out not to be the case due to IMS reporting changeshttp://seekingalpha.com/article/1158251-avanir-pharmaceuticals-is-nuedexta-soaring-out-of-its-sophomore-slump?source=yahoo
59
2/15/201322,411,985803,910 2.82.923.262.651,690,900-0.10-1.82Avanir Corporate Deck Presentation Slides Feb 2013. Launch of Nuedexta enters its third yearhttps://docs.google.com/file/d/0BynSySvZi_MFcjVNdHV4ZVg3X1k/edit
60
2/28/201321,949,574-462,411 2.722.762.882.69881,137-0.16-1.98New Study 02/25/13 ? ALS MS only. Next step should be use Variation II EMA additional indication route. Trial Link http://clinicaltrials.gov/show/NCT01799941
61
3/15/201320,640,366-1,309,208 3.062.953.132.691,543,0180.19-1.79 Appointment of Corinne Nevinny to Board of Directors. Collaboration with Department of Veterans, Pilot study for PBAhttp://finance.yahoo.com/news/avanir-pharmaceuticals-announces-research-collaboration-140000211.html
62
3/28/201320,090,575-549,791 2.752.873.062.71773,144-0.08-1.87EMA CHMP opinion moved to March. Link to EMA Web Site CHMP committee highlights http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/general/general_content_000245.jsp&mid=WC0b01ac058004d5c2
63
4/12/201320,283,743193,168 2.922.752.972.6808,900-0.12-1.99ABPI Knowledge Hub -  Global pharmaceutical industry and market Source: IMS Health World Review Analyst http://www.abpi.org.uk/industry-info/knowledge-hub/global-industry/Pages/industry-market-.aspx#fig4
64
4/30/201320,525,517241,774 3.193.083.862.811,981,1080.33-1.6604/25/2013, the EMA Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion,http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/002560/WC500142515.pdf
65
5/15/201319,799,294-726,223 3.23.183.393.051,069,8270.10-1.56Avanir Corporate Deck Presentation Slides  May 2013. http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9MTgxMzAzfENoaWxkSUQ9LTF8VHlwZT0z&t=1
66
5/31/201319,845,41646,122 3.323.333.433.131,068,2180.15-1.41Link to DB CC Transcripts May 29th 2013. Additional short positions at 06/12/2013 (4.22) are underwater, update later. https://docs.google.com/document/d/1k_tDTUSrMpw-i4lq51raP0JaCtI0h111x2jmRs5rLxc/edit
67
6/14/201319,949,960104,544 4.53.954.533.33,506,3000.62-0.79The FDA agrees to expedite pathway for  AVP-786. Mizuho initiates coverage with a Buy.  $10.00.  https://docs.google.com/document/d/1kAZXCr8NLJevvy3dvhJJm4dl5QsPNJF-W1ePVTl4J7Y/edit
68
6/28/201319,880,135-69,825 4.64.454.784.112,607,7900.50-0.29Press Release 25th June 2013 Avanir Pharmaceuticals Announces European Approval of NUEDEXTAhttps://docs.google.com/document/d/1b1FB539h2oOXUbEQ3MVCcFj5YbFDDyukaLyKs5l5uZE/edit
69
7/15/201319,935,64855,513 4.614.434.774.072,126,110-0.02-0.31Press Release Link Prime Study Completion, Opti Acquisition, Employee Grants. Yahoo raise I Yr target to $8.50https://docs.google.com/document/d/1nVyjgTBlxHGorCWZ7eNrqukOja8KCg1bt116ayLQEDg/edit
70
7/31/201318,628,683-1,306,965 4.714.75.094.51,757,7750.27-0.04Major Depressive Disorder, Treatment Resistant Phase 2 Clinical Trial verified: 18th July 2013    Yahoo= Year Target 9http://clinicaltrials.gov/show/NCT01882829
71
8/15/201319,230,540601,857 4.894.735.214.332,496,4810.03-0.01Avanir F3Q13 Results - Earnings Call Transcript 08/12/2013 Avanir Pharmaceuticals Announces Diabetes Co-Promotion Agreement with Merck Yahoo Target 9.81  14th August Sandoz Settle Nuedexta Litigationhttps://docs.google.com/document/d/11pxPn_QoAsiHfS6PU8ZjZJkNulq05SntRKRZ8RY41I8/edit
72
8/30/201318,249,592-980,948 5.15.025.324.712,839,4540.290.2822nd August Avanir Announces Publication of 'PRISM' Findings. PPS Average close goes to green for the first time since approval high of $5.80https://docs.google.com/document/d/1WAcRYAdTiG81EDTDlFYrT4yIHwGPSqKHvRQPjJAvQpw/edit
73
9/13/201317,847,037-402,555 4.085.3263.986,292,7660.300.5809/03/2013 AVNR announce patent settlement with Actavis. 09/06/2013 AVNE announce patent settlement with Wockhardt.Seeking Alpha Gravity Article Sep 11 2013, 12:48  Alleged Off-Label Marketing, Patent Woes And Other Issues May Spell Disaster For Avanir. Stock PPS Slumps on unfounded rumours. Jim Cramer reappears CafePharma postingshttps://docs.google.com/document/d/1cYvwQU2KGxHqks3f5x3QB5cmWlm5O8m6B9ix2J_DrSw/edit
74
9/30/201318,509,604662,567 4.234.314.64.083,208,936-1.01-0.43Avanir Pharmaceuticals Announces Publication of AVP-825 Pharmacokinetic Data in Journal "Headache"https://docs.google.com/document/d/1BP64cufLhBWAp2qVLrrqbft3XUHrpnNloHkP4n8kdh0/edit#heading=h.tjvs3h9722gd
75
10/15/201318,800,752291,148 4.484.544.744.112,170,7540.23-0.20NMDA Receptor Antagonists for Treatment of Depressionhttp://www.mdpi.com/1424-8247/6/4/480
76
10/31/201318,281,562-519,190 4.054.575.063.992,318,9750.03-0.17Avanir Pharmaceuticals, Inc. Investor Relations Day Conference Call October 29, 2013https://docs.google.com/document/d/1TPXRZSIwFJKlyrMc2rSHghMs_S9_TJX7MP-NeXz6AKI/edit
77
11/15/201317,884,835-396,727 4.594.274.6141,502,081-0.30-0.47November 4, AVNR Chief Commercial Officer, Rohan Palekar, invested $41,895.00 into 10,000 shares  Yahoo Target 10.21http://www.forbes.com/sites/dividendchannel/2013/11/11/land-this-bargain-even-cheaper-than-svp-palekar-did/?partner=yahootix
78
11/29/201317,526,396-358,439 4.444.314.714.171,700,0220.04-0.43Form 8 K Entry into a Material Definitive Agreement, Termination of a Materialhttps://docs.google.com/document/d/1xrMr23m57Fwbe2RKUbLfCRoxwV5jj9xFJeoQ_tjUOvg/edit
79
12/13/201317,838,417312,021 2.843.954.522.834,020,160-0.36-0.79Prime Study Results Disappoint and 4th Quarter 2013 CC Transcriptshttps://docs.google.com/document/d/1NVhRSVPaWeOuZBSzJysc4cy1DlK7GlftH1I8ZlovOWs/edit
80
12/31/201317,810,685-27,732 3.363.123.542.623,380,754-0.83-1.62Zack  AVNR Big move up of almost 20% on the 23rd. 24th Shareholder Alert LK, Investigation into AVNR announcedhttps://docs.google.com/document/d/1NWVs2jMePY_m-H73cv-ZAHuGbAS5CQUppRlm-Rhzd3I/edit
81
1/15/201417,147,945-662,740 3.813.363.843.052,166,4600.24-1.38Avanir Corporate Presentation Jan 2014 Slide Link https://docs.google.com/file/d/0BynSySvZi_MFSjIzWUpfamNBWlk/edit
82
1/31/201417,088,517-59,428 3.753.674.093.21,840,4000.31-1.07Avanir Pharmaceuticals Announces Submission of New Drug Application for AVP-825 for the Acute Treatment of Migrainehttps://docs.google.com/document/d/19i1Utsd3b9tlzXEPPrZhWMGzHunzczf7AqwEWbCe7eY/edit
83
2/14/201417,201,710113,193 4.043.724.383.341,864,9500.05-1.02Avanir Pharmaceuticals' CEO Discusses F1Q2014 Results - Earnings Call Transcripthttps://docs.google.com/document/d/1-pjIHzksfiwyNrAijSEByMsYOyl5NA0DANLl-Q0PZkk/edit
84
2/28/201416,951,290-250,420 4.164.074.323.642,583,0660.35-0.67KK Letter to shareHolders 2013https://docs.google.com/document/d/1g-KygGBBIpNMx0gwwD4CYvvnEDtYa1QQxcqSvwoTcAs/edit
85
3/14/201415,856,677-1,094,613 3.864.275.083.773,003,3700.20-0.47Avanir Announces Publication of Research Showing Dextromethorphan has Antidepressant-like Effects In Vivohttps://docs.google.com/document/d/184q4puGkLiE68vHpt6jldxZj1yefor1e2e5aXc0bgyo/edit
86
3/31/201415,841,400-15,277 3.673.814.273.452,513,727-0.46-0.93Avanir Pharmaceuticals Announces Acceptance of New Drug Application for AVP-825 for the Acute Treatment of Migrainehttps://docs.google.com/document/d/1Ymx18bzPf0VC5VgFu8l3XN1YPsP7amsY3oN1PkM7grQ/edit
87
4/15/201415,107,549-733,851 3.293.543.93.021,882,263-0.27-1.20Avanir Presentation Slides May 2014https://docs.google.com/file/d/0BynSySvZi_MFMG55NFgyOWRINlU/edit
88
4/30/201415,090,443-17,106 4.983.585.153.072,664,1400.04-1.16Avanir Pharmaceuticals Prevails in NUEDEXTA Patent Trial Resulting in Exclusivity Through 2026https://docs.google.com/document/d/1-pGZmTQ5H_fMYBaD20x2Wh1U067ghJ8kLKMHICyKtOA/edit
89
5/15/201416,193,0601,102,617 54.755.224.315,767,7271.170.01May 7, 2014, Amd No. 3 sales agreement with Cowen  the sale of up to an additional $50M of shares  & Sold to investor  https://docs.google.com/document/d/1Sx1rU-vh1K9LdlYjCSnekgasKzG5s1WDf4GdGBCTL68/edit#
90
5/30/201415,204,518-988,542 5.284.965.444.572,593,6100.210.22AVNR Completion of Patient Enrollment in Study of AVP-923 for the Treatment of Agitation in Patients with Alzheimer's Diseasehttps://docs.google.com/document/d/1IaOMM3hs6nRo5iX3L68aRBTsWM2-mfDA7R05WBGzeIQ/edit
91
6/13/201416,098,820894,302 5.735.355.774.892,199,7300.390.61Baker Bros added 11M Shares Disclosed...............................  Looking a bit deeper into the EU (3)            Link   https://docs.google.com/document/d/1DDnKt0OpK8u2cbS5VDE5Si9tNzks-Ax9ee1X2HShnYQ/edit
92
6/30/201416,062,764-36,056 5.645.475.895.242,282,0540.120.73AVNR Announces Positive Outcome of Phase IIIb Trial:  AVP-825 to Oral Sumatriptan for the Acute Treatment of Migrainehttps://docs.google.com/document/d/19BNTSV6WF4OFcUrj2B0h3PjGb-jBS5JidyNsqWrcMJk/edit
93
7/15/201416,313,790251,026 5.475.655.935.321,877,1200.180.91Clinical Trial  Nuedexta for the Prevention and Modification of Disease Progression in Episodic. Migraine Not Yet Recruitinghttp://clinicaltrials.gov/ct2/show/NCT02176018?term=Avanir&rank=15
94
7/31/201416,852,212538,422 5.215.35.645.131,586,750-0.350.56AVNR Announces Positive Early Results from PRISM II Study 07/016/14 See Clinical Trials link below for further info https://docs.google.com/document/d/1DsX4QhhTSn4J9dkeAXTPT0LrdBf86Jtr_uS7MLLCaf4/edit#heading=h.3ssjmgefspoh
95
8/15/201416,334,817-517,395 5.575.455.755.081,911,4360.150.7121ST July AVNR Announces FDA Acceptance of IND for AVP-786 for the Adjunctive Treatment of Major Depressive Disorderhttps://docs.google.com/document/d/18L1qyxlW1Dkpv9zmw-S1FeN09a5dqp-SuNUtOiaPj4w/edit
96
8/29/201416,252,325-82,492 6.225.936.245.572,207,9700.481.19Court Orders Orange Book Patent Delisting in NUEDEXTA Infringement Litigation; But What’s It Good For?https://docs.google.com/document/d/1eJv8aWvZ4lHnhq6yvyP1CptKTvZvv1JJrSr9KOj1wPg/edit
97
9/15/201417,055,971803,646 12.496.9313.835.8511,859,7701.002.19Positive Phase II Trial Results for AVP-923 in Treatment of Agitation in Patients with Alzheimer's Diseasehttps://docs.google.com/document/d/1BqK1aNPstnx3TNLq5CaSMSefGAF_YyAvcfLtq_KqS_c/edit
98
9/30/201415,432,827-1,623,144 11.9211.6712.210.459,863,1184.746.93AVNR Announces Closing of Public Offering of C Stock and Full Exercise of Underwriters' Option to Purchase Additional Shareshttps://docs.google.com/document/d/1B85HyvPzOn70uHOQrnFSA5UVoK10FUxcrTBOcTAt1nQ/edit
99
10/15/201416,894,3341,461,507 11.5211.6212.3911.054,879,754-0.056.88AVNR Presentation of AVP-923 Phase II Results in Agitation in Patients with Alzheimer's Disease at the ANA Meeting https://docs.google.com/document/d/1RhbEwKdC2Zi5so2xIgA7-MqG1tWCXq9Hp7IDFXLeRPE/edit
100
10/31/201414,894,454-1,999,880 12.9411.9313.6110.614,720,8250.317.19AVNR Announces Publication of Pivotal Phase III Results from AVP-825 Acute Migraine Study in the Journal "Headache"https://docs.google.com/document/d/1qUGi8VxhxRXVxefV8CGkje-54o5GbOnVcVbSO2m3c8E/edit
Loading...
 
 
 
Short Postion S1
AVNR Transcript 12 12 2012
Sheet8
Sheet7
KK Letter to Share Holders year end 2012